Mark M. Udden, MD, Chair
Dr. Udden, a board-certified hematologist and internist, is Chief of Benign Hematology and Professor of Medicine at Baylor College of Medicine in Houston, Texas. He is Chief of Hematology at the Ben Taub General Hospital and Harris Health Smith Clinic. He is also an attending physician in the Baylor Clinic and consults at Baylor Saint Luke's Medical Center and the Texas Children's Hospital Pavilion for Women. He has a special interest in sickle cell disease and hematology of pregnancy. He also co-chairs the second-year medical student course in hematology/oncology and has an active teaching role for resident and fellowship training at Baylor.
He has served at Baylor as Core Clerkship Director for Internal Medicine from 1990 to 2007 and Chairman of the Longitudinal Ambulatory Care Experience course from 1994 to 1999. He was an adjunct Assistant then Associate Professor in the Biomedical Engineering Department at Rice University from 1983 until 1992.
Dr. Udden is Chair of the American Board of Internal Medicine (ABIM) Hematology Board. He is a fellow of the American College of Physicians. At Baylor, he has received numerous teaching awards including the Barbara and Corbin J. Robertson, Jr. Presidential Award for Excellence in Education in 2008 and the Master Clinician Lifetime Award in 2013.
He received his undergraduate degree from the Massachusetts Institute of Technology and his medical degree from The University of Texas Southwestern Medical School. He completed his residency in internal medicine and a fellowship in hematology at Baylor College of Medicine.
As of September 2020, Dr. Udden reported the following external relationships:
Dr. Udden serves in significant roles with the following organization, receiving reimbursement or compensation as listed:
- American Society of Hematology, participating in Work Force Summit and Committee for Hematology-Focused Fellowship, receiving reimbursement for travel expenses.
Dr. Udden also reported compensation for medical legal consulting, with a portion paid to Baylor College of Medicine.
Paul T. Adams, MD
Dr. Adams is in private practice at Genesee Hematology/Oncology PC. He is the Hematology/Oncology Fellowship Director and Director of Hematology/Oncology Services at Genesys Regional Medical Center. He is also Medical Director of Medical Oncology for Ascension Michigan. Dr. Adams serves as a faculty member at the University of Michigan and is a member of American Board of Internal Medicine Hematology Board.
Dr. Adams is a graduate of the Wayne State University School of Medicine. His internal medicine residency was performed at Henry Ford Hospital in Detroit, Michigan, followed by a hematology/oncology fellowship at the University of Michigan.
As of May 2021, Dr. Adams reported no external relationships.
Beth M. Faiman, PhD, RN, MSN, ANP-BC, AOCN
Dr. Faiman is employed as a Nurse Practitioner in the Department of Hematology and Oncology at the Cleveland Clinic in Cleveland, Ohio. She received the 2012 Excellence in Medical Oncology and 2013 Commendation for Patient and Nursing Education Awards sponsored by The Oncology Nursing Society; the 2015 Dean's Legacy Award for PhD Studies from Case Western, and was named the Leukemia and Lymphoma Society's Woman of the Year for Cleveland and Akron Ohio, 2016. She is an appointed delegate on the International Myeloma Foundation Nurse Leadership Board, Editor-in-Chief of The Oncology Nurse APN/PA and on the editorial board of ASH Clinical News. She serves as a member of the American Board of Internal Medicine Hematology Board. Dr. Faiman is an active author and educator on the topics of plasma cell dyscrasias, hematology and symptom management.
She led the development of myeloma nurse management guidelines, and influenced cancer care practice by presenting at 18 international and 210 US national/regional conferences. She served as lecture chair of 3 international and 63 national conferences. She has edited several books, authored many chapters, and written numerous articles relating to the diagnosis and treatment of blood cancers, treatment adherence, and cancer symptom management and remains active in clinical trials research.
Dr. Beth Faiman received a bachelor of science in nursing and registered nurse certification at Ursuline College in Pepper Pike, Ohio, completed in 1996. She received a master of science in nursing and certification as an adult nurse practitioner at Kent State University in Kent, Ohio in 2002 and a PhDher doctorate from Case Western Reserve University in 2014. Dr. Faiman holds an advanced oncology nurse certification through Oncology Nursing Certification Corporation.
As of December 2018, Dr. Faiman reported the following external relationships:
Funding for clinical trial expenses, paid to the Cleveland Clinic Foundation, from the following companies:
- Celgene, for consulting and clinical trial expenses.
- Janssen, for a trial of dartumumab.
- Amgen, for a trial of carfilzomib and denosumab.
- Bristol-Myers Squibb, for a trial of elotuzumab.
Service on data and safety monitoring boards for the following company, with compensation for travel expenses:
- Janssen, for clinical research in randomized trials for cancer.
Work as an author or editor for following companies, with compensation as listed:
- American Society of Hematology, receiving compensation as Associate Editor of Advanced Practice.
Meghan Gutierrez is the Chief Executive Officer of the Lymphoma Research Foundation, the nation's largest nonprofit organization devoted to funding lymphoma research and education, advancing both the study of new cancer therapies and improved patient care.
A government relations and health care policy specialist, Ms. Gutierrez has pursued an array of public policy issues during her career, ranging from mental health parity and rare disease awareness to medical technology and the treatment of chronic disease. Following her work as a Congressional staff member for one of the U.S. House of Representatives' foremost leaders on health care policy, she served as a health policy and communications advisor for several national nonprofit and educational institutions, including Columbia University and the Partnership for a Drug-Free America.
Ms. Gutierrez was named Lymphoma Research Foundation Chief Executive Officer in 2014. In this role she represents the Foundation and the lymphoma community before numerous audiences, including the U.S. Congress, Food and Drug Administration, National Institutes of Health, pharmaceutical industry and health insurance payers. She has written and lectured extensively about the needs of cancer patients and served on committees and panels of the American Society of Clinical Oncology, American Society of Hematology, Institute of Medicine, and National Cancer Institute, among others. She has received numerous national awards and recognition for her work to champion the needs of people with cancer and underserved patient populations. Additionally, Ms. Gutierrez was among 100 women listed in Crain's Notable Women in Health Care, recognizing her commitment to the healthcare industry and moving it toward gender equality. Similarly, Ms. Gutierrez was recognized by PR News as a Top Women in Healthcare for her national leadership in healthcare.
Ms. Gutierrez earned her bachelor’s degree from the University of Iowa.
As of December 2019, Dr. Gutierrez reported the following external relationships:
Ms. Gutierrez is employed by the Lymphoma Research Foundation. It offers a national continuing medical education program, Lymphoma Rounds, and oversees the staff developing this program.
Ishmael A. Jaiyesimi, DO
Dr. Jaiyesimi specializes in hematology-oncology and is the Director of the Hematology- Oncology Fellowship Program and Department Chair for the Hematology – Oncology Department at William Beaumont Hospital – Royal Oak and is on staff at Beaumont in Troy, Michigan. He is certified by the American Board of Internal Medicine and its sub-specialty boards in Medical Oncology and Hematology.
Dr. Jaiyesimi has been training internal medicine residents, medical students and fellows in hematology/oncology for almost three decades. Active in the clinical research of cancer and the Cancer Clinical Trials Office (CCTO), he is also a Professor of Medicine in Hematology/ Oncology at Oakland University William Beaumont School of Medicine. Dr. Jaiyesimi is a fellow of the American College of Physicians; a member of the American Society of Clinical Oncology, American Medical Association, American Society of Hematology, American Osteopathic Association, and Oakland County Medical Society.
A graduate of the University of Minnesota, College of Pharmacy in Minneapolis with a bachelor's of science degree in pharmacy and a master's degree in social and administrative pharmacy, Dr. Jaiyesimi attended medical school and graduated Western University of Health Sciences in Pomona, California where he received his doctor of osteopathic medicine degree. He continued in medicine by completing an internal medicine residency at William Beaumont Hospital in Royal Oak, Michigan, and completed a fellowship in hematology and oncology at the University of Texas, M.D. Anderson Cancer Center in Houston, Texas. I am certified by the American Board of Internal Medicine and its sub-specialty boards, medical oncology, and hematology.
As of September 2020, Dr. Jaiyesimi reported the following external relationships.
Dr. Jaiyesimi serves in significant roles with the following organization, receiving reimbursement or compensation as listed:
- Leukemia & Lymphoma Society, Michigan, Trustee Member, without compensation.
Dr. Jaiyesimi also reports that he gives didactic lectures in medical oncology and hematology to their hematology and oncology fellows, residents, and medical students at Oakland University William Beaumont School of Medicine.
Marc J. Kahn, MD, MBA
Dr. Kahn is the Peterman-Prosser Professor and Senior. Associate Dean at Tulane University School of Medicine where he has appointments in the Departments of Internal Medicine and Pharmacology in addition to the Tulane AB Freeman School of Business. Dr. Kahn’s research interests include medical education, non-malignant hematology and healthcare finance. He is board certified in Internal Medicine, Medical Oncology and Hematology.
Dr. Kahn is a member of the American Board of Internal Medicine Hematology Board. He served on the Board of Directors for the National Residency Matching Program. He also serves several leadership roles with the American College of Physicians (ACP) including serving as Chair of the Scientific Program Committee for 2018 and 2020 and as a contributor or editor for MKSAP 13 through 18. Dr. Kahn was elected a Master of the ACP in 2018. Additionally, he has served as National Chair of the Association of American Medical Colleges Group on Student Affairs. He has also held leadership positions with the American Society of Hematology (ASH), including serving as contributor or editor of the ASH SAP for the first five editions. He has also served as Vice Chair of the ASH Committee on Educational Affairs and served as the Inaugural Sr. Director of the ASH Medical Educator’s Institute. Dr. Kahn was elected a Fellow of the Royal College of Physicians, London.
Dr. Kahn received his bachelor and medical degrees from the University of Pennsylvania where he completed his internal medicine residency, chief medical residency and hematology/medical oncology fellowship. Dr. Kahn completed his master’s degree in business administration at Tulane’s AB Freeman School of Business in 2010.
As of July 2019, Dr. Kahn reported the following external relationships:
Work funded by educational grants from industry, from the following companies:
- Eli Lilly & Company, for medical student travel stipend.
Work as an author or editor for following company, with compensation as listed:
- Springer, eligible to receive royalties for Basic Business Skills for Healthcare Providers.
Dr. Kahn serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- National Residency Matching Program, Board Member, Chair of Violations Review Committee, Executive Committee Member, receiving reimbursement for travel expenses.
- American College of Physician, Chair of Scientific Program Committee, Member of Chapter Education Committee, travel, receiving reimbursement for travel expenses.
- American Society of Hematology, Vice Chair of Committee on Educational Affairs, Senior Director of American Society of Hematology Medical Educators Institute, Chair of Highlights of American Society of Hematology Committee, Member of Communications Committee, receiving reimbursement for travel expenses.
Selina M. Luger, MD
Dr. Luger is a Professor of Medicine at the University of Pennsylvania where she is a member of the Hematologic Malignancies Program of the Abramson Cancer Center at the Hospital of the University of Pennsylvania. She is a member of the Royal College of Physicians and Surgeons in Canada where she is board certified in Internal Medicine ( RCPSC) and she has active board certification in Hematology ( ABIM) and inactive but eligible for certification in Internal Medicine and Oncology (ABIM). She serves as a member of the American Board of Internal Medicine Hematology Board.
She is actively involved with the American Society of Hematology where she is a member of the Committees on Scientific Affairs and she is co-Chair of the Women in Hematology Working Group. She is an Associate Editor of Blood. She is actively involved in clinical research in the Acute Leukemias and related myeloid disorders and serves as the co-Chair of the Leukemia Committee and the Adolescent and Young Adult Subcommittee of the Eastern Cooperative Oncology Group.
Dr. Luger received her undergraduate degree at Harvard, and her medical degree at McGill University.
As of September 2020, Dr. Luger reported the following external relationships:
Funding for clinical trial expenses and staff, paid to the University of Pennsylvania, from the following companies:
- Onconova Therapeutics
Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:
- Agios, for serving on an advisory board, receiving reimbursement for travel expenses and honoraria.
- Bristol-Myers Squibb, for serving on an advisory board, receiving honoraria.
- LOXO, for serving on an advisory board, receiving honoraria.
Work as an author or editor for following company, with compensation as listed:
- American Society of Hematology, receiving compensation as Associate Editor for Blood.
Dr. Luger serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- American Society of Hematology, Committee Member and Working Group co-Chair, receiving reimbursement for travel expenses.
- Eastern Cooperative Oncology Group, Committee Co-chair, without compensation.
Marc S. Zumberg, MD
Dr. Zumberg is Professor and Section Chief Non-Malignant Hematology at the University of Florida College of Medicine, Gainesville, Florida. He is board certified in Hematology.
Dr. Zumberg has been a faculty member at the University of Florida since completing his combined fellowship in Hematology and Medical Oncology in 2000. He currently serves as Professor of Medicine and as Section Chief of Non-Malignant Hematology. From 2006-2014, he served as Associate Professor of Medicine and from 2000-2006, as Assistant Professor of Medicine. Dr. Zumberg has served as Medical Director for Therapeutic Apheresis for LifeSouth Community Blood Centers since 2000.
Dr. Zumberg served on the American Society of Hematology (ASH) committee on training programs from 2008-2015. He served as the ASH Liaison on Maintenance of Certification to the American Board of Internal Medicine (ABIM) Hematology Board from 2015-2017, and currently serves as a member of the ABIM Hematology Board. He was an inaugural faculty member at the ASH Medical Educators Institute where he subsequently served as faculty. He was recognized as the basic science teacher of the year at the University of Florida Medical School in 2017 and the hematology course he directs was voted best basic science course by the graduating medical students in 2016-2018.
Dr. Zumberg received a bachelor's degree in neurobiology in 1990 and his medical degree in 1994, both from the University of Michigan. He completed an internal medicine residency in 1997 and a hematology-oncology fellowship in 2000, both at the University of Florida.
As of August 2020, Dr. Zumberg reported the following external relationships:
Dr. Zumberg serves in significant roles with the following organization, receiving reimbursement or compensation as listed:
- American Society of Hematology, Highlights of American Society of Hematology lecturer, member of several committees, receiving consulting fees and reimbursement for travel expenses.
- Best Doctors, receiving honoraria.
Dr. Zumberg is also a medical director for NCF Diagnostics.